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Title: 
Use of unlicensed medicines by prescribers, pharmacists and patients across primary and secondary care: A qualitative 
study  
 
Abstract:  (Please refer to instructions to authors and example abstract) 
Focal Points: 
Ẅ This study aimed to explore perceptions of healthcare professionals and patients about the use of unlicensed 
medicines (ULMs) 
Ẅ Education and training of healthcare professionals is likely to be a key enabler in improving use of  ULMs 
Ẅ This study revealed differences in perceptions between patients and professionals, and across care settings 
 
Introduction: 
An unlicensed medicine (ULM) is a product which does not have a marketing authorisation from the MHRA1. Areas that 
have not previously been explored include; how and why prescribers choose to initiate them, how and where pharmacists 
source them, patient use and awareness of ULMs. This research study aimed to explore the perceptions of healthcare 
professionals and patients on the use of ULMs. 
 
Methods: 
Semi-structured face-to-face interviews were conducted with prescribers (n=11), pharmacists (n=10) and patients (n=7) 
from primary and secondary care. A theoretical sampling approach was used; grounded theory analysis led to the 
development of themes and informed participant selection. Interviews were audio recorded and transcribed verbatim. 
Themes were presented back to participants (n=8) using two focus groups (healthcare professionals and patients 
separately). Ethical approvals from the NHS and University were obtained prior to completion of this research. 
 
Results: 
All interviewees had experience of either; prescribing, reviewing, dispensing or taking unlicensed medicines. Participants 
discussed several ULM scenarios including imported medicines, ‘Specials’, food supplements, ‘off-label’ use of 
medicines and investigational medicinal products. Several themes were identified across the data by healthcare 
professionals and patients in primary and secondary care, including: 
• Healthcare professionals’ awareness of when they were using an ULM and their definition of an ULM  
• Perceptions of safety of ULMs was elicited, including the lack of safety and efficacy data compared to licensed 
products and the perceived under-reporting of adverse effects 
• Provision of information and whether patients were likely to be informed about the unlicensed status of their 
medicines, who the person to inform them should be and what information patients would want 
• The place of unlicensed medicine use in the clinical management of a patient, including whether licensed alternatives 
were tried first 
• Trust as an important aspect in the use of unlicensed medicines, this was apparent throughout the interviews and 
between all actors 
 
Lack of education and training for healthcare professionals around what an ULM is and the associated implications of 
their use, coupled with a lack of information seems to perpetuate problems identified in the use of ULM. Cost 
implications associated with ULMs was a strong theme among primary care participants, however, many secondary care 
participants lacked an awareness of the associated costs which could lead to under-utilisation of viable alternatives. Costly 
and burdensome regulatory processes for medicines licensing were often cited for the use of ULMs and seemed to 
legitimise their routine use in practice. 
 
Discussion: 
The lack of marketing authorisation creates many issues in the use of ULMs, including a lack of access to information and 
reduced intelligence around their safety and efficacy. Despite this they are generally perceived as safe. The regulatory 
implications of using ULMs and the potential variability between products, does not seem to be well understood. 
Consideration of how the patient will use the medication and the provision of suitable written information seems to be 
inconsistently considered. There is a need for training and the development of mutually agreed standards on the use of 
ULMs to inform a more consistent approach to their use by both healthcare professionals and patients. The study was 
limited by only being able to include those who were willing to participate. 
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